We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

resource that aims to "improve health equity and advance personalised medicine." Pfizer is the first big pharma company to sign up to make use of the platform, which used machine learning and ...

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.